Senescent cancer cell-derived nanovesicle as a personalized therapeutic cancer vaccine

免疫原性 癌症 抗原 癌症疫苗 免疫系统 癌症研究 癌细胞 医学 免疫学 免疫疗法 佐剂 癌症免疫疗法 内科学
作者
Jihye Hong,Mungyo Jung,Cheesue Kim,Mikyung Kang,Seokhyeong Go,Heesu Sohn,Sangjun Moon,Sungpil Kwon,Seuk Young Song,Byung‐Soo Kim
出处
期刊:Experimental and Molecular Medicine [Springer Nature]
卷期号:55 (3): 541-554 被引量:10
标识
DOI:10.1038/s12276-023-00951-z
摘要

Abstract The development of therapeutic cancer vaccines (TCVs) that provide clinical benefits is challenging mainly due to difficulties in identifying immunogenic tumor antigens and effectively inducing antitumor immunity. Furthermore, there is an urgent need for personalized TCVs because only a limited number of tumor antigens are shared among cancer patients. Several autologous nanovaccines that do not require the identification of immunogenic tumor antigens have been proposed as personalized TCVs. However, these nanovaccines generally require exogenous adjuvants (e.g., Toll-like receptor agonists) to improve vaccine immunogenicity, which raises safety concerns. Here, we present senescent cancer cell-derived nanovesicle (SCCNV) as a personalized TCV that provides patient-specific tumor antigens and improved vaccine immunogenicity without the use of exogenous adjuvants. SCCNVs are prepared by inducing senescence in cancer cells ex vivo and subsequently extruding the senescent cancer cells through nanoporous membranes. In the clinical setting, SCCNVs can be prepared from autologous cancer cells from the blood of liquid tumor patients or from tumors surgically removed from solid cancer patients. SCCNVs also contain interferon-γ and tumor necrosis factor-α, which are expressed during senescence. These endogenous cytokines act as adjuvants and enhance vaccine immunogenicity, avoiding the need for exogenous adjuvants. Intradermally injected SCCNVs effectively activate dendritic cells and tumor-specific T cells and inhibit primary and metastatic tumor growth and tumor recurrence. SCCNV therapy showed an efficacy similar to that of immune checkpoint blockade (ICB) therapy and synergized with ICB. SCCNVs, which can be prepared using a simple and facile procedure, show potential as personalized TCVs.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
大个的应助被xzl123采纳,获得10
刚刚
1秒前
1秒前
ZGD完成签到 ,获得积分10
2秒前
桃子发布了新的文献求助10
3秒前
west完成签到,获得积分10
3秒前
徐师傅完成签到,获得积分10
3秒前
小二郎的应助被312采纳,获得10
5秒前
大模型的应助被so采纳,获得10
5秒前
5秒前
章鱼小丸子完成签到 ,获得积分10
6秒前
6秒前
左旋多巴完成签到,获得积分0
6秒前
qwzh完成签到,获得积分10
6秒前
水煮电吹风的应助被hc采纳,获得10
6秒前
lydia完成签到,获得积分10
7秒前
活泼糜发布了新的文献求助10
7秒前
7秒前
7秒前
大东东完成签到,获得积分10
7秒前
8秒前
无心的小凡完成签到,获得积分10
8秒前
科研通AI2S的应助被zz采纳,获得10
8秒前
8秒前
闪闪新晴发布了新的文献求助30
8秒前
小雪要上岸完成签到,获得积分10
8秒前
8秒前
晨儿完成签到 ,获得积分10
9秒前
所所的应助被随意采纳,获得10
10秒前
10秒前
阔达的皮皮虾完成签到,获得积分10
10秒前
远方发布了新的文献求助10
11秒前
12秒前
ali8ba发布了新的文献求助10
13秒前
科研通AI2S的应助被简朴煜城采纳,获得10
13秒前
13秒前
LSF关注了科研通微信公众号
13秒前
受伤白安发布了新的文献求助10
13秒前
yjx完成签到,获得积分10
13秒前
F_ken完成签到,获得积分10
14秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
八旗制度の研究 600
Boundaries and Bodhisattvas 500
高分子基功能界面水蒸发材料与应用研究 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8182147
求助须知:如何正确求助?哪些是违规求助? 9571790
关于积分的说明 21820037
捐赠科研通 7778601
什么是DOI,文献DOI怎么找? 3433617
关于科研通互助平台的介绍 2557786
邀请新用户注册赠送积分活动 2479652